0435-5088008
Contact:
4008465777
×
-
About Us
News & Events
-
01-24Tonghua Dongbao 2021 estimated results: Net profit attributable to parent up 43.40% YoY On the evening of January 24, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its financial estimated results for 2021. Specifically, the revenue is estimated to hit RMB 3.252 billion, up 12.45% YoY, the net profit attributable to owners of the parent company grew 43.40% YoY to RMB 1.334 billion, the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, rose 17.54% YoY to RMB 1.123 billion. The basic earning per share (EPS) was RMB 0.66, up 43.48% YoY.
-
12-27Tonghua Dongbao: Clinical trial application for BC Combo accepted Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Tonghua Dongbao") received the notification of acceptance from the National Medical Products Administration (NMPA) on the clinical trial application for BC Combo (THDB0207 injection), a soluble insulin glargine and insulin lispro injection. The acceptance number is CXSL2101513 Guo.
-
12-16Tonghua Dongbao: URAT1 inhibitor (THDBH130 Tablets) is approved for clinical trial On December 15, 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice of approval (No. CXHL2101548 and CXHL2101549) from the Center for Drug Evaluation of the National Medical Products Administration for the clinical trial of its URAT1 inhibitor (THDBH130 Tablets).
-
11-26Tonghua Dongbao's insulin products win the bid for centralized procurement, increasing the company's market share On November 26, 2021, China's Joint Procurement Office (JPO) released the preliminary results of the sixth round of volume-based procurement (VBP) tender for insulin. Tonghua Dongbao's insulin products won the bid as Category B candidates, which conforms to the management's expectation and its business plan. Benefiting from the diverse product portfolio and economies of scale, the Company can further increase its market share while earning a steady stream of profits, which lays a solid foundation for its vision of becoming an explorer and leader of novel drug R&D in the field of endocrinology.
-
11-12Tonghua Dongbao wins Golden Bridge Award for Most Valuable Pharmaceutical Company of the Year On November 11, 2021, the 2021 Thinking Finance Annual Investors Meeting and Golden Bridge Awards Ceremony was held in Shanghai. Tonghua Dongbao won the Golden Bridge Award for the Most Valuable Pharmaceutical Company of the Year.
-
10-27Tonghua Dongbao records 41.28% YoY increase in net profit attributable to parent company for first 3Qs On the evening of October 27, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its quarterly report for Q3 2021. In...